Skip to main content
Equibles
INDP logo

INDP · Indaptus Therapeutics, Inc.

Track INDP — free

Use INDP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.14 -0.02 (-1.72%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on its current operating plans and available financial resources, the Company believes that it has sufficient liquidity to fund its planned operations and investment activities through June 30, 2027. The Company may further strengthen its capital position through additional public or private equity or debt financings as appropriate to support its strategic objectives and long-term development. As a result of these uncertainties, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$151.90M
Shares
133.24M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.14 Open$1.16 Day$1.10–1.18 52W close$0.94–6.50 Avg vol 30d610K Short int124K · 0.1% float · 1.0d Short vol40% DataJun 2025–Aug 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Jun 27, 2025; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross Death cross
Price vs 200-day avg −49%
below
Price vs 50-day avg −45%
below
RSI (14) 39
neutral
MACD trend Positive
52-week position 4%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −12%
trailing
6-month return −39%
trailing
YTD return −61%
this year
Relative strength −52%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+50% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.09% of float · ▲ +32.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
9 holders — mid 3-yr range
Squeeze score 34
low risk · 0–100
Fundamentals
Fair
EPS growth +52%
Y/Y
Free cash flow $-14.8M
Quant / Vol
risk profile
Very High
Volatility 195%
annualized · 1-yr
Max drawdown −86%
past year
ATR 18.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 1 · 2
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−49% Bearish
Price vs 50-day avg
−45% Bearish
RSI (14)
39 Neutral
MACD trend
Positive Bullish
52-week position
4% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+50% holders QoQ · +6 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.09% of float · ▲ +32.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
9 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 4% Range high $7
vs 200-day avg -49% vs 50-day avg -45% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INDP
Indaptus Therapeutics, Inc.
this stock
$151.90M -60.8% — — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +2.9% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
9
% held
0.3%
Net QoQ
+314.4K sh
Top holder
HRT FINANCIAL LP
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
123.7K
Days to cover
1.0d
Change
+30.6K sh
View
Short Volume
Short vol %
40%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
4.0K
Value
$6.9K
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
40.6%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-20.8M
EPS diluted
$-21.58
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
18
View
Exempt Offerings
Offering
$5.0M
Filed
Jun 20, 2025
View

Performance

Raw-price comparisons begin at the captured split on Jun 27, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
INDP -11.6% -11.6% -39.0% -11.6% -60.8%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -12.1% -14.6% -52.5% -14.6% -73.6%
Key facts CIK 1857044 CUSIP 45339J204 13F (30d) 8 filings 8 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)